keyword
MENU ▼
Read by QxMD icon Read
search

breast tumor

keyword
https://www.readbyqxmd.com/read/29045658/exendin-4-a-glucagon-like-peptide-1-receptor-agonist-attenuates-breast-cancer-growth-by-inhibiting-nf-%C3%AE%C2%BAb-activation
#1
Chikayo Iwaya, Takashi Nomiyama, Shiho Komatsu, Takako Kawanami, Yoko Tsutsumi, Yuriko Hamaguchi, Tsuyoshi Horikawa, Yasuteru Yoshinaga, Shinichi Yamashita, Tomoko Tanaka, Yuichi Terawaki, Makito Tanabe, Kazuki Nabeshima, Akinori Iwasaki, Toshihiko Yanase
Incretin therapies have received significant attention because of their tissue-protective effects, which extend beyond those associated with glycemic control. Cancer is a primary cause of death in patients with diabetes mellitus. We previously reported anti-prostate cancer effects of the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonist exendin-4 (Ex-4). Breast cancer is one of the most common cancers in female patients with type 2 diabetes mellitus and obesity. Thus, we examined whether GLP-1 action could attenuate breast cancer...
October 13, 2017: Endocrinology
https://www.readbyqxmd.com/read/29045642/patient-and-tumor-characteristics-and-their-influence-on-early-therapy-persistence-with-letrozole-in-postmenopausal-patients-with-early-breast-cancer
#2
N Nabieva, S Kellner, T Fehm, L Häberle, J de Waal, M Rezai, B Baier, G Baake, H-C Kolberg, M Guggenberger, M Warm, N Harbeck, R Wuerstlein, J-U Deuker, P Dall, B Richter, G Wachsmann, C Brucker, J W Siebers, N Fersis, T Kuhn, C Wolf, H-W Vollert, G-P Breitbach, W Janni, R Landthaler, A Kohls, D Rezek, T Noesselt, G Fischer, S Henschen, T Praetz, V Heyl, T Kühn, T Krauss, C Thomssen, A Hohn, H Tesch, C Mundhenke, A Hein, C Rauh, C M Bayer, A Jacob, K Schmidt, E Belleville, S Y Brucker, S Kümmel, M W Beckmann, D Wallwiener, P Hadji, P A Fasching
Background: Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole. Patients and methods: The EvAluate-TM Study is a prospective, multicenter, noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive EBC in the early therapy phase...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045554/veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus-placebo-with-carboplatin-paclitaxel-in-patients-with-brca1-2-locally-recurrent-metastatic-breast-cancer-randomized-phase-ii-study
#3
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli, S M Domchek, M Friedlander, B Kaufman, J E Garber, Y Shparyk, E Chmielowska, E H Jakobsen, V Kaklamani, W Gradishar, C K Ratajczak, C Nickner, Q Qin, J Qian, S P Shepherd, S J Isakoff, S Puhalla
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045543/a-predictive-model-of-pathological-response-based-on-tumor-cellularity-and-tumor-infiltrating-lymphocytes-celtil-in-her2-positive-breast-cancer-treated-with-chemo-free-dual-her2-blockade
#4
P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, M Oliveira, P Galvan, N Martínez, B Bermejo, M Vidal, S Pernas, R López, M Muñoz, I Garau, L Manso, J Alarcón, E Martínez, V Rodrik-Outmezguine, J C Brase, P Villagrasa, A Prat, E Holgado
Background: The presence of stromal tumor-infiltrating lymphocytes (TILs) is associated with increased pathological complete response (pCR) and improved outcomes in HER2-positive early breast cancer (BC) treated with anti-HER2-based chemotherapy. In the absence of chemotherapy, the association of TILs with pCR following anti-HER2 therapy-only is largely unknown. Patients and methods: The PAMELA neoadjuvant trial treated 151 women with HER2-positive BC with lapatinib and trastuzumab (and hormonal therapy if hormone receptor [HR]-positive) for 18 weeks...
October 12, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045526/lag-3-tumor-infiltrating-lymphocytes-in-breast-cancer-clinical-correlates-and-association-with-pd-1-pd-l1-tumors
#5
S Burugu, D Gao, S Leung, S K Chia, T O Nielsen
BACKGROUND: Novel immune checkpoint blockade strategies are being evaluated in clinical trials and include targeting the lymphocyte activation gene 3 (LAG-3) checkpoint, alone or in combination with PD-1/PD-L1 blockade. We investigated LAG-3 expression and its prognostic value in a large series of breast cancer patients, and correlated LAG-3 expression with key biomarkers including PD-1 and PD-L1. EXPERIMENTAL DESIGN: LAG-3 expression was evaluated by immunohistochemistry (IHC) on two tissue microarray series incorporating 4322 breast cancer primary excision specimens (N=330 in the training and N= 3,992 in the validation set) linked to detailed clinico-pathological, biomarker and long term clinical outcome data...
September 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045460/conjugated-nanoliposome-with-the-her2-neu-derived-peptide-gp2-as-an-effective-vaccine-against-breast-cancer-in-mice-xenograft-model
#6
Atefeh Razazan, Javad Behravan, Atefeh Arab, Nastaran Barati, Leila Arabi, Zahra Gholizadeh, Mahdi Hatamipour, Amin Reza Nikpoor, Amir Abbas Momtazi-Borojeni, Fatemeh Mosaffa, Mohamad Hosein Ghahremani, Mahmoud Reza Jaafari
One of the challenging issues in vaccine development is peptide and adjuvant delivery into target cells. In this study, we developed a vaccine and therapeutic delivery system to increase cytotoxic T lymphocyte (CTL) response against a breast cancer model overexpressing HER2/neu. Gp2, a HER2/neu-derived peptide, was conjugated to Maleimide-mPEG2000-DSPE micelles and post inserted into liposomes composed of DMPC, DMPG phospholipids, and fusogenic lipid dioleoylphosphatidylethanolamine (DOPE) containing monophosphoryl lipid A (MPL) adjuvant (DMPC-DMPG-DOPE-MPL-Gp2)...
2017: PloS One
https://www.readbyqxmd.com/read/29045452/prospective-multicenter-french-study-evaluating-the-clinical-impact-of-the-breast-cancer-intrinsic-subtype-prosigna%C3%A2-test-in-the-management-of-early-stage-breast-cancers
#7
Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff, Cyril Foa, Rémy Salmon, Aurélie Roulot, Florence Lerebours, Anne Salomon, Nadeem Ghali, Pascale Morel, Qianyi Li, Anne Cayre, Jean-Marc Guinebretière, John Hornberger, Frédérique Penault-Llorca, Roman Rouzier
PURPOSE: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results...
2017: PloS One
https://www.readbyqxmd.com/read/29045292/ovarian-metastases-of-breast-cancers-with-signet-ring-cells-a-report-of-17-cases-including-14-krukenberg-tumors
#8
Jennifer A Bennett, Robert H Young, Ai-Ying Chuang, Melinda F Lerwill
Krukenberg tumor, defined as metastatic adenocarcinoma to the ovary containing at least 10% signet ring cells, usually arises from the stomach but can also originate from other sites. We reviewed 17 metastatic breast carcinomas to the ovary with signet ring cells to potentially identify features indicative of mammary origin as opposed to other possible primary sites. The patients ranged from 41 to 76 (mean, 53.6) yr. Fourteen had a prior history of invasive breast carcinoma (invasive ductal carcinoma, 4; invasive lobular carcinoma, 3; adenocarcinoma not otherwise specified, 3; carcinoma with ductal and lobular features, 2; and unspecified carcinoma, 2) and metastases were identified 2 to 284 (mean, 79) mo after the original diagnosis...
October 17, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29045232/imaging-neoadjuvant-therapy-response-in-breast-cancer
#9
Amy M Fowler, David A Mankoff, Bonnie N Joe
The use of neoadjuvant systemic therapy in the treatment of breast cancer patients is increasing beyond the scope of locally advanced disease. Imaging provides important information in assessing response to therapy as a complement to conventional tumor measurements via physical examination. The purpose of this article is to discuss the advantages and limitations of current assessment methods, as well as review functional and molecular imaging approaches being investigated as emerging techniques for evaluating neoadjuvant therapy response for patients with primary breast cancer...
November 2017: Radiology
https://www.readbyqxmd.com/read/29044896/support-vector-machine-for-breast-cancer-classification-using-diffusion-weighted-mri-histogram-features-preliminary-study
#10
Igor Vidić, Liv Egnell, Neil P Jerome, Jose R Teruel, Torill E Sjøbakk, Agnes Østlie, Hans E Fjøsne, Tone F Bathen, Pål Erik Goa
BACKGROUND: Diffusion-weighted MRI (DWI) is currently one of the fastest developing MRI-based techniques in oncology. Histogram properties from model fitting of DWI are useful features for differentiation of lesions, and classification can potentially be improved by machine learning. PURPOSE: To evaluate classification of malignant and benign tumors and breast cancer subtypes using support vector machine (SVM). STUDY TYPE: Prospective. SUBJECTS: Fifty-one patients with benign (n = 23) and malignant (n = 28) breast tumors (26 ER+, whereof six were HER2+)...
October 16, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29044882/sox2-communicates-with-tregs-through-ccl1-to-promote-the-stemness-property-of-breast-cancer-cells
#11
Yingxi Xu, Xiaoli Dong, Pingping Qi, Yujie Ye, Wenzhi Shen, Liang Leng, Lina Wang, Xuefei Li, Xiaohe Luo, Yanan Chen, Peiqing Sun, Rong Xiang, Na Li
As an important component of tumor microenvrionment, CD4(+) CD25(+) Tregs reduce antitumor immunity, promote angiogenesis and metastasis in breast cancer. However, their function in regulating the "stemness" of tumor cells and the communication between Tregs and cancer stem cells (CSCs) remain elusive. Here, we disclose that the primarily cultured Tregs isolated from breast-tumor-bearing Foxp3-EGFP mouse up-regulate the stemness property of breast cancer cells. Tregs increased the side-population and the ALDH(br) population of mouse breast cancer cells, promoted their sphere formation in a paracrine manner and enhanced the expression of stemness genes, such as Sox2 etc...
October 16, 2017: Stem Cells
https://www.readbyqxmd.com/read/29044505/diagnostic-pathology-of-early-systemic-cancer-erbb2-gene-amplification-in-single-disseminated-cancer-cells-determines-patient-survival-in-operable-esophageal-cancer
#12
Martin Hoffmann, Sophie Pasch, Thomas Schamberger, Matthias Maneck, Birte Möhlendick, Sarah Schumacher, Gero Brockhoff, Wolfram Trudo Knoefel, Jakob Izbicki, Bernhard Polzer, Nikolas H Stoecklein, Christoph A Klein
Early metastatic dissemination and evolution of disseminated cancer cells (DCCs) outside the primary tumor is one reason for the failure of adjuvant therapies because it generates molecular geno- and phenotypes different from primary tumors which still underlie therapy decisions. Since ERBB2 amplification in esophageal DCCs but not in primary tumor cells predict outcome, we aimed to establish an assay with diagnostic reliability for single DCCs or circulating tumor cells (CTCs). For this we evaluated copy number alterations of more than 600 single DCCs from multiple cancer types to define reference regions suitable for quantification of target regions, such as ERBB2...
October 16, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29044377/heparosan-coated-liposomes-for-drug-delivery
#13
Rachel S Lane, F Michael Haller, Anais A E Chavaroche, Andrew Almond, Paul L DeAngelis
Liposomal encapsulation is a useful drug delivery strategy for small molecules, especially chemotherapeutic agents such as doxorubicin. Doxil® is a doxorubicin-containing liposome ("dox-liposome") that passively targets drug to tumors while reducing side effects caused by free drug permeating and poisoning healthy tissues. Polyethylene glycol (PEG) is the hydrophilic coating of Doxil® that protects the formulation from triggering the mononuclear phagocyte system (MPS). Evading the MPS prolongs dox-liposome circulation time thus increasing drug deposition at the tumor site...
November 1, 2017: Glycobiology
https://www.readbyqxmd.com/read/29044199/fluorescence-coded-dna-nanostructure-probe-system-to-enable-discrimination-of-tumor-heterogeneity-via-a-screening-of-dual-intracellular-microrna-signatures-in-situ
#14
Seung Won Shin, Byoung Sang Lee, Kisuk Yang, Lunjakorn Amornkitbamrung, Min Su Jang, Bo Mi Ku, Seung-Woo Cho, Jung Heon Lee, Hojae Bae, Byung-Keun Oh, Myung-Ju Ahn, Yong Taik Lim, Soong Ho Um
Since the delivery kinetics of different cell types are different, the signal from the target cell is greatly affected by the noise signal of the diagnostic system. This is a major obstacle hindering the practical application of intracellular diagnostic systems, such as tumor heterogeneity. To address these issues, here we present a microRNA detection platform using fluorescence-encoded nanostructured DNA-based probes. The nanostructured DNA was designed to include molecular beacons for detecting cytosolic microRNA as well as additional fluorophores...
October 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29044153/tripalmitin-nanoparticle-formulations-significantly-enhance-paclitaxel-antitumor-activity-against-breast-and-lung-cancer-cells-in-vitro
#15
María Carmen Leiva, Raúl Ortiz, Rafael Contreras-Cáceres, Gloria Perazzoli, Iryna Mayevych, Juan Manuel López-Romero, Francisco Sarabia, Jose Manuel Baeyens, Consolación Melguizo, Jose Prados
Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid nanoparticles (NPs) of glyceril tripalmitate (tripalmitin) loaded with PTX (Tripalm-NPs-PTX) including modifications by the addition of hexa(ethylene glycol), β-cyclodextrin and macelignan were developed. All NPs-PTX formulations displayed excellent hemocompatibility and significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3 and T47D) and lung (A549, NCI-H520 and NCI-H460) cancer cells...
October 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29043992/correlation-of-the-ultrasound-imaging-of-breast-cancer-and-the-expression-of-molecular-biological-indexes
#16
Jie Xu, Feng Li, Fengling Chang
This paper aims to 137 cases of breast malignant tumors confirmed by surgery and pathology were collected. All patients received ultrasound examination and were not treated by radiotherapy or chemotherapy before operation. The preoperative ultrasound images of breast cancer patients and postoperative pathological characteristics of paraffin sections were retrospectively observed. Ultrasound indicators included tumor size, shape, ratio of the longest/shortest dimension, edge of the spiculation and peripheral hyperechoic halo sign, internal echo types, micro calcification, posterior echo types, blood flow and signs of lymph node metastasis...
July 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29043471/nanostructured-lipid-carrier-co-loaded-with-doxorubicin-and-docosahexaenoic-acid-as-a-theranostic-agent-evaluation-of-biodistribution-and-antitumor-activity-in-experimental-model
#17
Renata S Fernandes, Juliana O Silva, Samuel V Mussi, Sávia C A Lopes, Elaine A Leite, Geovanni D Cassali, Valbert N Cardoso, Danyelle M Townsend, Patrick M Colletti, Lucas A M Ferreira, Domenico Rubello, André L B de Barros
PURPOSE: Nanotheranostic platforms, i.e., the combination of both therapeutic and diagnostic agents on a single platform, are emerging as an interesting tool for the personalized cancer medicine. Therefore, the aim of this work was to evaluate the in vivo properties of a Tc-99m-labeled nanostructured lipid carrier (NLC) formulation, co-loaded with doxorubicin (DOX) and docosahexaenoic acid (DHA), for theranostic applications. PROCEDURES: NLC-DHA-DOX were prepared busing the hot melting homogenization method using an emulsification-ultrasound and were radiolabeled with Tc-99m...
October 17, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29043292/phyllodes-tumors-with-and-without-fibroadenoma-like-areas-display-distinct-genomic-features-and-may-evolve-through-distinct-pathways
#18
Fresia Pareja, Felipe C Geyer, Rahul Kumar, Pier Selenica, Salvatore Piscuoglio, Charlotte K Y Ng, Kathleen A Burke, Marcia Edelweiss, Melissa P Murray, Edi Brogi, Britta Weigelt, Jorge S Reis-Filho
Breast fibroepithelial lesions (fibroadenomas and phyllodes tumors) are underpinned by recurrent MED12 exon 2 mutations, which are more common in fibroadenomas and benign phyllodes tumors. TERT promoter hotspot mutations have been documented in phyllodes tumors, and found to be more frequent in borderline and malignant lesions. Several lines of evidence suggest that a subset of phyllodes tumors might arise from fibroadenomas. Here we sought to investigate the genetic differences between phyllodes tumors with fibroadenoma-like areas vs...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29043114/expression-of-stk11-gene-and-its-promoter-activity-in-mcf-control-and-cancer-cells
#19
Asma Alkaf, Abdulaziz Al-Jafari, Tanveer A Wani, Somaya Alqattan, Seema Zargar
Serine/threonine kinase gene (STK11) is identified as tumor suppressor gene whose mutation can lead to Peutz-Jeghers syndrome (PJS). STK11 is emerging as a multifunctional protein, it activates 14 different AMP-activated protein kinase (AMPK) family members, important in the regulation of cell polarity, cell cycle arrest, energy and hemostasis. Present study was designed to evaluate STK11 mRNA expression in MCF-7 cancer and MCF-10 normal breast cells lines. mRNA expression was studied by real-time PCR. Further, human STK11 promoter construct was fused to a luciferase reporter and transfected into both MCF-7 and MCF-10 cells to identify the promoter activity in these cells...
December 2017: 3 Biotech
https://www.readbyqxmd.com/read/29042957/ursolic-acid-inhibits-breast-cancer-growth-by-inhibiting-proliferation-inducing-autophagy-and-apoptosis-and-suppressing-inflammatory-responses-via-the-pi3k-akt-and-nf-%C3%AE%C2%BAb-signaling-pathways-in-vitro
#20
Juan Luo, Yan-Ling Hu, Hong Wang
Breast cancer, which is the second leading cause of cancer-associated mortality in women worldwide, develops from breast tissue. Chemotherapy is the most commonly used therapy to treat breast cancer. However, a number of natural plant-derived products have been suggested as alternative therapies to treat different types of cancer, such as breast cancer. The aim of the present study was to determine the anti-tumor effects of ursolic acid and its effect on apoptosis and inflammation in breast cancer cells. The anti-cancer effects of ursolic acid were evaluated in vitro using flow cytometry, western blotting and reverse transcription-quantitative polymerase chain reaction...
October 2017: Experimental and Therapeutic Medicine
keyword
keyword
31630
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"